Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1995-6-1
|
| pubmed:abstractText |
Few reports exist detailing results of multimodality treatment for adenocarcinoma of the esophagus. We have treated 28 such patients using a preoperative regimen consisting of two courses of cisplatin and 5-fluorouracil with radiation (either 3,000 or 3,600 cGy). There were 25 men and 3 women (mean age, 62.9 years; range, 35 to 86 years), and 16 patients were known to have Barrett's esophagus. Dysphagia was present for a mean of 2.7 months, and the average weight loss was 6.5 kg. Tumors ranged from 2 to 10 cm in length (mean, 5.2 +/- 1.8 cm) with American Joint Committee on Cancer clinical stage I in 2 patients, stage II in 19 patients, and stage III in 7. Dysphagia improved in 23 patients (82%), and in 8 (29%) no tumor was detected during radiologic and endoscopic staging after neoadjuvant therapy. Four patients refused operation. Esophagectomy via standard Ivor Lewis approach was accomplished in 20 of 24 patients (87%) undergoing operation. There were no operative deaths, and mean hospital stay was 15.5 +/- 11.6 days. Four patients (17%) were complete responders with no tumor in the resected specimen. Actuarial survival in the 28 patients at 1, 2, and 3 years is 71%, 28%, and 20% respectively. Of the 20 esophagectomy patients, 6 are alive with no evidence of disease at 10, 50, 54, 70, 77, and 84 months. Three of these were complete responders. Only 1 of the 8 patients no undergoing resection is alive at 16 months with no evidence of disease after further radiotherapy and chemotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0003-4975
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
59
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1085-90; discussion 1090-1
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:7733702-Adenocarcinoma,
pubmed-meshheading:7733702-Adult,
pubmed-meshheading:7733702-Aged,
pubmed-meshheading:7733702-Aged, 80 and over,
pubmed-meshheading:7733702-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7733702-Cisplatin,
pubmed-meshheading:7733702-Combined Modality Therapy,
pubmed-meshheading:7733702-Esophageal Neoplasms,
pubmed-meshheading:7733702-Esophagectomy,
pubmed-meshheading:7733702-Female,
pubmed-meshheading:7733702-Fluorouracil,
pubmed-meshheading:7733702-Humans,
pubmed-meshheading:7733702-Male,
pubmed-meshheading:7733702-Middle Aged,
pubmed-meshheading:7733702-Neoplasm Recurrence, Local,
pubmed-meshheading:7733702-Postoperative Complications,
pubmed-meshheading:7733702-Radiotherapy Dosage,
pubmed-meshheading:7733702-Survival Rate
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Multimodality therapy for adenocarcinoma of the esophagus.
|
| pubmed:affiliation |
Division of Cardiothoracic Surgery, St. Louis University Health Sciences Center, Missouri 63110-0250, USA.
|
| pubmed:publicationType |
Journal Article
|